We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Methods Evaluated to Detect Asymptomatic Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 24 Jul 2019
Print article
Image: The Multiskan GO microplate spectrophotometer (Photo courtesy of Thermo Fisher Scientific).
Image: The Multiskan GO microplate spectrophotometer (Photo courtesy of Thermo Fisher Scientific).
Visceral leishmaniasis (VL) is caused by Leishmania infantum [synonymous L. chagasi] in the New World or L. donovani in the Old World, VL can be classified as an anthroponotic or zoonotic disease because it is transmitted between humans and others mammals, such as dogs.
Visceral leishmaniasis in humans presents with fever, anemia, and splenomegaly and can be lethal if not treated. Nevertheless, the majority of L. infantum-infected individuals don’t manifest symptoms, and remain so provided they are not immunosuppressed. Direct and indirect methods are used for diagnosis of VL.

A team of scientists working with the Ribeirão Preto School of Medicine (Ribeirão Preto, Brazil) included in a study of patients with VL before and after treatment, who were hospitalized in the city of Teresina, and volunteers without any symptom of the disease residing in the same city. Sample collections were carried out between August and November 2017. Samples obtained from healthy volunteers residing in the city of Ribeirão Preto, were used as control of non-endemic area. The diagnosis of VL was confirmed by the positivity of amastigote forms in samples of bone marrow aspirate stained by Giemsa, and confirmed by cell culture in NNN medium.

Immunochromatographic tests (IC) were performed using Kalazar Detect Rapid, and the OnSite Leishmania IgG/IgM Combo test. An in-house enzyme-linked immunosorbent assay (ELISA) was performed and read on a Multiskan GO microplate spectrophotometer. DNA extraction was performed using 200 μL of total peripheral blood. IFN-γ-induced protein 10 (IP-10) and monokine induced by IFN-γ (MIG) were quantified in the study in 50 μL of plasma from whole blood soluble Leishmania antigen (SLA)-stimulated or non-SLA-stimulated using the BD Cytometric Bead Array Human Flex Set.

The scientists reported that Kalazar Detect and OnSite detected, respectively, 76% and 64% of patients presenting with active VL; 50% and 57% of patients remained positive in these tests, respectively, after treatment. Of the healthy participants in the study who were living in the endemic area, only 1.7% were positive with both of the IC tests. On the other hand, reactivity in ELISA tests revealed that 13% of these individuals presented asymptomatic infections; among VL patients, 84% presenting with active disease were reactive in ELISA and after treatment, 55.5% were seropositive. L. infantum DNA was present in the blood of 37.9% of infected individuals living in the endemic area, while IP-10 and MIG biomarkers were detected in 26.7% of them.

The authors concluded that the association of different techniques can detect asymptomatic infections, however, more investigation is necessary to develop ideal biomarkers that are simple to use in the clinic and in field studies in areas endemic for visceral leishmaniasis. The study was published on July 1, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ribeirão Preto School of Medicine

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.